Fibrate Drugs Market Size | COVID-19 Impact Analysis | Forecast to 2028
The global fibrate drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Fibrate drugs are the therapeutics that belong to the class of amphipathic carboxylic acids that lower triglyceride levels in the blood by inhibiting hepatic extraction of free fatty acids which results in increased activity of the endothelial lipoprotein lipase. The major factors that are driving the growth of the fibrate drugs market include the increased rate of cardiovascular diseases across the globe. Additionally, the overweight or obese population in developed countries and sedentary lifestyles leads to cardiovascular disorders which are some other key factors for the growth of the market. Various clinical trials have demonstrated that fenofibrate triggers elevated levels of cholesterol and apolipoprotein. According to the study published by the National Institute of Health, in 2020, adults aged 65 and older are more likely than younger people to suffer from CVD.
To Request a Sample of our Report on Fibrate Drugs
Market: https://www.omrglobal.com/request-sample/fibrate-drugs-market
Some of the major players in the market include Pfizer Inc, Mylan NV,
Sanofi SA, Aurobindo Pharma, and Abbott Laboratories. The market players are
contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical expansion,
partnerships and collaborations, and new product launches, to stay competitive
in the market. For instance, in November 2021, Lupin launched generic
Fenofibrate capsules, which is used for the treatment of high cholesterol and
triglyceride levels in the blood in the US. It works by increasing the natural
substances (enzymes) that break down fats in the blood. The company launched
the generic version in the strength of 30 mg and 90 mg in the US. Additionally,
in April 2020, Dr. Reddy’s Laboratories Ltd announced the launch of fenofibrate
tablets in the US.
Further, in September 2021 Aurobindo Pharma Ltd. has received final
approval from US Food and drug administration for its abbreviated new drug
application Fenofibrate capsules USP 67mg,134, mg and 200 mg. These capsules
are an AB-rated generic equivalent to the reference listed drug, Tricor
Capsules of AbbVie Inc.
Market Coverage
·
The market number available for – 2022-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Drug Type
·
By Product Type
·
By Distribution
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Pfizer Inc, Mylan NV, Sanofi SA, Aurobindo Pharma,
and Abbott Laboratories.
(Get 15% Discount on Buying this Report)
A
full Report of Fibrate Drugs Market is Available @ https://www.omrglobal.com/industry-reports/fibrate-drugs-market
Global Fibrate Drugs Market Report by Segment
By Drug Type
·
Clofibrate
·
Gemfibrozil
·
Fenofibrate
·
Others
By Product Type
·
Branded
·
Generics
By Distribution Channel
·
Hospital Pharmacy
·
Retail Pharmacy
·
Online Pharmacy
Global Fibrate Drugs Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment